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ABSTRACT
Abnormal alternative splicing of tau exon 10 results
in imbalance of 3R-tau and 4R-tau expression,
which is sufficient to cause neurofibrillary degener-
ation. Splicing factor SC35, a member of the super-
family of the serine/arginine-rich (SR) proteins,
promotes tau exon 10 inclusion. The molecular
mechanism by which SC35 participates in tau exon
10 splicing remains elusive. In the present study, we
found that tau pre-mRNA was coprecipitated by
SC35 tagged with HA. Mutation of the SC35-like
exonic splicing enhancer located at exon 10 of tau
affected both the binding of SC35 to tau pre-mRNA
and promotion of tau exon 10 inclusion, suggesting
that SC35 acts on the SC35-like exonic splicing en-
hancer to promote tau exon 10 inclusion. Dyrk1A
(dual-specificity tyrosine-phosphorylated and regul-
ated kinase 1A) phosphorylated SC35 in vitro and
interacted with it in cultured cells. Overexpression
of Dyrk1A suppressed SC350s ability to promote
tau exon 10 inclusion. Downregulation of Dyrk1A
promoted 4R-tau expression. Therefore, upregulation
of Dyrk1A in Down syndrome brain or Alzheimer’s
brain may cause dysregulation of tau exon 10
splicing through SC35, and probably together with
other splicing factors, leading to the imbalance in
3R-tau and 4R-tau expression, which may initiate or
accelerate tau pathology and cause neurofibrillary
degeneration in the diseases.
INTRODUCTION
Tau is a neuronal microtubule-associated protein that
promotes microtubule (MT) assembly and stabilizes MT
network. Therefore, tau plays important roles in neuronal
morphogenesis, axon polarity and axonal transport (1,2).
Aggregation of hyperphosphorylated tau in the brain ca-
uses diverse set of sporadic and familial neurodegenerative
diseases called tauopathies (3,4).
The human tau gene lies on the long arm of chro-
mosome 17 and contains 16 exons from which 6 different
tau isoforms are generated in the adult central nervous
system by alternative splicing of exons 2, 3 and 10 (5).
The alternative splicing of exon 10 of the tau gene results
in the presence or absence of the second MT-binding
repeats, leading to the expression of tau containing
either four (4R-tau) or three MT-binding repeats
(3R-tau) (6,7). Approximately equal amount of 3R-tau
and 4R-tau are expressed in normal adult human
brain (8,9).
At least 39 different mutations in the tau gene have been
identiﬁed from patients with frontotemporal dementia
with Parkinsonism linked to chromosome 17 (FTDP-17)
(10–12). More than a half of these mutations only alters
splicing of exon 10 and consequently disrupts 3R-tau/
4R-tau balance but does not disrupt tau’s primary
sequence (13). Thus, alteration in the 3R-tau/4R-tau
ratio is sufﬁcient to trigger neurodegeneration and demen-
tia. Dysregulation of alternative splicing of human tau
exon 10 is one of the important etiologic mechanisms in
the pathogenesis of tauopathies.
Alternative splicing is regulated by multiple exonic and
intronic cis-element and trans-acting splicing factors.
Serine/arginine-rich (SR) proteins are one group of the
splicing factors involved in alternative splicing (14,15).
All SR proteins are highly conserved in eukaryotes and
have a modular organization. They contain an N-terminal
RNA-recognition motif (RRM) that interacts with the
pre-mRNA and a C-terminal arginine–serine-rich (RS)
domain that promotes protein–protein interactions
within the splicing complex (16,17).
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monoclonal antibodies directed against puriﬁed
spliceosomes (18). Previous studies reported that the
extent of SC35 recruitment to alternatively spliced tran-
scripts of tau exon 10 is related to exon 10 inclusion (19).
Tau exon 10 contains a SC35-like enhancer at 50-end
(20,21). However, there is no direct evidence that SC35
acts on SC35-like enhancer to promote tau exon 10
inclusion.
SR protein is a phosphoprotein. Its function is highly
regulated by the phosphorylation. Several kinases could
phosphorylate SR proteins and regulate their function
(22–25). We recently reported that dual-speciﬁcity
tyrosine-phosphorylated and regulated kinases 1A
(Dyrk1A) phosphorylates SF2/ASF, a SR protein and
inhibits its promotion of tau exon 10 inclusion (26).
Dyrk1A is a proline- and arginine-directed Ser/Thr
kinase. It lies at the Down syndrome (DS) critical region
of chromosome 21 and contributes to several phenotypes
of DS in transgenic mice (27,28). Individuals with DS
develop Alzheimer-type neuroﬁbrillary degeneration as
early as the fourth decade of life (29). Overexpression of
Dyrk1A due to an extra-copy of chromosome in DS brain
leads to the dysregulation of tau exon 10, resulting in an
increase in 3R-tau expression and causing early onset of
tau pathology in DS brain (26). The early onset of tau
pathology in DS could also be caused or promoted by
over-production of amyloid-b peptide as a result of an
extra copy of the gene for amyloid-b precursor protein,
which is also located on chromosome 21. Overexpression
of Dyrk1A changes the distribution of SC35 from speckles
to more diffuse in nucleus (30), suggesting that Dyrk1A
may also modulate SC350s function.
In the present study, we investigated the molecular
mechanism by which SC35 regulates tau exon 10 splicing
and Dyrk1A regulates SC35-mediated tau exon 10
splicing. The ﬁndings of this study suggest that SC35
promotes exon 10 inclusion by acting on the SC35-like
enhancer and that Dyrk1A phosphorylates SC35 and
suppresses its function in promotion of tau exon 10
inclusion.
MATERIALS AND METHODS
Plasmids and antibodies
pCEP4/SC35-HA was a gift from Dr Tarn of the Institute
of Biomedical Sciences, Academia Sinica, Taiwan.
Mammalian expression vector pcDNA3.1 containing
either rat Dyrk1A or kinase-dead Dyrk1AK188R were
described previously (26). pCI/SI9–SI10 containing a tau
minigene, SI9/SI10, comprising tau exons 9, 10 and 11,
part of introns 9 and 10 was as described (31). Mouse
monoclonal antibody 8D9 was raised against a
histidine-tagged protein containing the ﬁrst 160 residues
of rat Dyrk1A (32). Rabbit polyclonal anti-HA, mouse
monoclonal anti-HA and mouse monoclonal anti-b-actin
were from Sigma (St Louis, MO, USA). Rabbit polyclonal
anti-tau (R134d) was described previously (33).
Peroxidase-conjugated anti-mouse and anti-rabbit IgG
were obtained from Jackson ImmunoResearch
Laboratories (West Grove, PA, USA); tetramethyl rhoda-
mine isothiocyanate (TRITC)-conjugated goat anti-rabbit
IgG, and ﬂuorescein isothiocyanate (FITC)-conjugated
goat anti-mouse IgG, siRNAs of human or mouse
Dyrk1A, and siRNA of mouse SC35 were from Santa
Cruz Biotechnology (Santa Cruz, CA). The ECL kit was
from Thermo Scientiﬁc (Rockford, IL, USA), and [g-
32P]
ATP and [
32P] orthophosphate were from MP
Biomedicals (Irvine, CA, USA). Alkaline phosphatase
from bovine calf intestine was from Sigma (St Louis,
MO, USA)
Plasmid construction and DNA mutagenesis
pGEX-2T/SC35 was constructed by PCR ampliﬁcation
from pCEP4/SC35 and subcloned into pGEX-2T to ex-
press GST-SC35 protein. The deletion mutations of SC35
were generated by amplifying an individual fragment,
which contains part of the SC35 coding region into the
HindIII–XhoI sites of pCEP4. Mutants of SI9/SI10 were
created by site-directed mutagenesis using KOD-Plus-
Mutagenesis kit (TOYOBO) with primers (forward, 50gg
ctaccaaaggtgcGgataattaataagaagctggatctta30, and reverse,
50taagatccagcttcttattaattatcAgcacctttggtagcc30) for SI9/
SI10E10A5G, primers (forward, 50ctaccaaaggtgcaTataattaa
taagaagctggatcttag30, and reverse, 50ctaagatccagcttcttattaa
ttatTtgcacctttggtag30) for SI9/SI10E10G6A and primers
(forward,50tggctaccaaaggtgattaataagaagctggatcttagcaac30,
and reverse, 50gttgctaagatccagcttcttattaatcacctttggta
gcca30) for SI9/SI10E103-9.
Cell culture and transfection
COS-7, HEK-293T, N2a, 3T3, SH-SY5Y and HeLa cells
were maintained in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum (Invitrogen,
Carsbad, CA, USA) at 37 C (5% CO2). Transfections
were performed with Lipofectamine 2000 (Invitrogen,
Carsbad, CA, USA) or FuGene 6 (Roche, Indianapolis,
IN), according to the manufacture’s instructions.
Expression and puriﬁcation of recombinant SC35
For puriﬁcation of GST-SC35, pGEX-2T/SC35 plasmid
was transformed into BL21 (DE3) host strain for expres-
sion. A 1 l culture of Escherichia coli harboring pGEX-2T/
SC35 plasmid was grown at 37 C to OD600 &0.6, and
induced with 0.5mM IPTG at 16 C overnight before har-
vesting by centrifugation. Cells were re-suspended in 30ml
of lysis buffer (50mM Tris–HCl, pH 7.8, 150mM NaCl,
1mM DTT, 1mM EDTA and protease inhibitor cocktail)
and lysed with sonication. All puriﬁcation procedures
were carried out at 4 C. The total soluble fraction was
recovered by centrifugation at 36000g for 60min, and
loaded onto 10ml of glutathione sepharose beads. The
resin was washed with 2M NaCl high salt buffer
(50mM Tris–HCl, pH 7.8, 1mM DTT, 1mM EDTA,
10% glycerol) and subsequently with 50mM NaCl low
salt buffer. The GST-fused SC35 bound to GST beads
was eluted with 10mM glutathione in 50mM Tris–HCl,
pH 8.0, 50mM NaCl and dialyzed against 50mM Tris–
HCl, pH 7.4). The puriﬁed GST-SC35 was aliquoted and
stored at  80 C.
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cells, pCEP4-SC35 was transfected into HEK-293T Cells
with FuGENE 6 for 48h, and then cells were lysed in
0.5ml of IP lysis/wash buffer (Pierce Crosslink
Immunoprecipitation Kit). One milligram of cell lysate
protein was added to protein G-Sepharose beads
cross-linked to anti-HA and incubated overnight at 4 C.
After extensively washing, SC35 was eluted in three suc-
cessive 100ml fractions with elusion buffer provided in the
kit and neutralized with 1M Tris.
Phosphorylation of SC35 by Dyrk1A in vitro
For phosphorylation of SC35 by Dyrk1A in vitro,
GST-SC35 or GST (0.2mg/ml) was incubated with various
concentrations of Dyrk1A in a reaction buffer consisting
of 50mM Tris–HCl, pH 7.4, 10mM b-mercaptoethanol,
0.1mM EGTA, 10mM MgCl2 and 0.2mM [g-
32P] ATP
(500cpm/pmol). After incubation at 30 C for 30min, the
reaction was stopped by adding an equal volume of 2 
Laemmli sample buffer and boiling. The reaction products
were separated by SDS–PAGE. Incorporation of
32P was
detected by exposure of the dried gel to phosphorimaging
system (BAS-1500, Fuji ﬁlm).
Dephosphorylation of SC35 by alkaline
phosphatase in vitro
SC35 was overexpressed in HEK-293T cells and immno-
precipitated with anti-HA crosslinked onto protein G
beads as described above. The immunocomplex on the
beads was dephophorylated with alkaline phosphatae in
reaction buffer (50mM Tris–HCl, pH 8.5, 10mg/ml apro-
tinin, 10mg/ml leupeptine, 10mg/ml pepstatin and 1mM
AEBSF) for 30min at 37 C. The dephosphorylated
product was eluted with 2  Laemmli buffer and boiling
and subjected to western blot analysis.
GST pull down
GST or GST-SC35 was puriﬁed by afﬁnity puriﬁcation
with glutathione Sepharose without elution from the
beads. Beads coupled with GST or GST-SC35 were
incubated with crude extract from rat brain homogenate
in buffer (50mM Tris–HCl, pH 7.4, 8.5% sucrose, 50mM
NaF, 1mM Na3VO4, 0.1% Triton X-100, 2mM EDTA,
1mM phenylmethylsulfonyl ﬂuoride, 10mg/ml aprotinin,
10mg/ml leupeptin and 10mg/ml pepstatin). After 4h
incubation at 4 C, the beads were washed with washing
buffer (50mM Tris–HCl, pH 7.4, 150mM NaCl and
1mM dithiothreitol) six times and the bound proteins
were eluted by boiling in Laemmli sample buffer, and
the samples were subjected to western blot analysis.
CO-IMMUNOPRECIPITATION
HEK-293T cells were co-transfected with pCEP4-SC35-
HA and pcDNA3.1-Dyrk1A for 48h. The cells were
washed twice with phosphate-buffered saline (PBS) and
lyzed by sonication in lysate buffer containing phosphat-
ase and protease inhibitors (50mM Tris–HCl, pH 7.4,
150mM NaCl, 50mM NaF, 1mM Na3VO4,2 m M
EDTA, 1mM phenylmethylsulfonyl ﬂuoride, 2mg/ml
aprotinin, 2mg/ml leupeptin and 2mg/ml pepstatin).
Insoluble materials were removed by centrifugation;
Protein G beads were incubated with anti-HA overnight
at 4 C, and then the antibody bound beads were incubated
with the cell lysate. After a 4h incubation at 4 C, the
beads were washed with lysate buffer twice and with
Tris-buffered saline twice, and bound proteins were
eluted by boiling in Laemmli sample buffer. The samples
were subjected to western blot analysis with the indicated
primary antibodies.
Co-localization study
HeLa cells were plated in 24-well plates onto coverslips 1
day prior to transfection at 30–40% conﬂuence. These
cells were transfected with HA-tagged SC35 constructs
or co-transfected with Dyrk1A as described above. Two
days after transfection, the cells were washed with PBS
and ﬁxed with 4% paraformaldehyde in PBS for 30min
at room temperature. After washing with PBS, the cells
were blocked with 10% goat serum in 0.2% Triton X-100/
PBS for 2h at 37 C and incubated with rabbit anti-HA
(1:200) and mouse anti-Dyrk1A (8D9, 1:5000) overnight
at 4 C. After washing and incubation with secondary
antibodies (TRITC-conjugated goat anti-rabbit IgG and
FITC-conjugated goat anti-mouse IgG, 1:200), the cells
were washed extensively with PBS and incubated with
5mg/ml Hoechst 33342 for 5min at room temperature.
The cells were washed with PBS, mounted with
Fluoromount-G and visualized with a Leica TCSSP2
laser-scanning confocal microscope.
Quantitation of tau exon 10 splicing by reverse
transcription–PCR
Total cellular RNA was isolated from cultured cells by
using an RNeasy mini kit (Qiagen GmbH). Six hundred
nanograms of total RNA was used for ﬁrst-strand cDNA
synthesis with oligo (dT)18 by using an Omniscript reverse
transcription kit (Qiagen GmbH). PCR was performed by
using Prime-STARTM HS DNA Polymerase (Takara Bio
Inc., Otsu, Shiga, Japan) with primers (forward 50-GGTG
TCCACTCCCAGTTCAA-30 and reverse 50-CCCTGGT
TTATGATGGATGTTGCCTAATGAG-30) for trans-
fected pCI/SI9–SI10, and with primers (forward 50-AAC
ACCGCCCACCCGGGAG-30 and reverse 50-GTCTGTC
TTGGCTTTGGCATTCTC-30) for endogenous mouse
tau to measure alternative splicing of tau exon 10 under
conditions: denaturation for 5min at 98 C was followed
by 30 cycles with denaturation for 10s at 98 C, annealing
for 15s at 55 C, polymerization for 30s at 72 C and a
ﬁnal extension for 10min at 72 C. The PCR products
were resolved on 1.5% agarose gels and quantitated
using the Molecular Imager system (Bio-Rad).
Electrophoretic mobility shift assay
Tau RNA primer of the wild-type SC35-like element 50-G
UGCAGAUAAUUAAUAAGAAGCUGGAUCUU-30
(Tau-RNA) or RNA primer of SC35-like element deleted
50-GUAUUAAUAAGAAGCUGGAUCUU-30 (Tau-
RNASC35-like) was labeled with [g-
32P]ATP (4500 Ci/mM)
using T4 polynucleotide kinase (New England Biolabs)
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(Amersham Biosciences). To perform electrophoretic
mobility shift assay (EMSA), the immunopuriﬁed SC35
in 50mM Tris–HCl buffer (pH 7.5) containing 50–mM
NaCl, 1mM EDTA and 1mM dithiothreitol was mixed
with
32P-labeled wild-type SC35-like RNA primer or
SC35-like enhancer deleted RNA primer in a total
volume of 10ml. The reaction mixture was incubated at
37 C for 40min, and analyzed with a 6% non-denaturing
polyacrylamide gel, which was pre-run at 100V for
10min. Electrophoresis was carried out in TBE buffer
(89mM Tris borate, 2mM EDTA) at 100V for 60min.
The gel was dried and visualized with a PhosphorImager
(BAS-1500, Fujiﬁlm). The RNA substrates used in all ex-
periments were at 2.4nM, and the amounts of proteins
were indicated in the ﬁgure legends.
RNA immunoprecipitation
The RNA immunoprecipitation (RNA-IP) experiment
was performed as described (34–36). Brieﬂy, HEK-293T
cells co-transfected with pCEP4/SC35 and pCI/SI9–SI10
were crosslinked with 1% formaldehyde for 10min at
room temperature. After quenching with 125mM
glycine, the cells were lyzed in lysis buffer (16.7mM
Tris–HCl, pH 8.1, 0.01% SDS, 1.1% Triton X-100,
1.2mM EDTA, 167mM NaCl, 1  Roche protease inhibi-
tors cocktail and 50 U/ml RNasin Plus RNase Inhibitor)
on ice for 10min, and centrifuged at 2000g for 5min to
pellet nuclei. The nuclear fraction was sonicated in buffer
B (50mM Tris–HCl, pH 8.1, 1% SDS, 10mM EDTA, 1 
protease inhibitors cocktail and 50U/ml RNasin Plus
RNase Inhibitor). After centrifugation at 16000g for
10min, the supernatant was subject to immunopre-
cipitation with anti-HA in IP buffer (16.7mM Tris–HCl,
pH 8.1, 167mM NaCl, 0.01% SDS, 1.1% Triton X-100,
1.2mM EDTA, 1  protease inhibitors cocktail and 50U/ml
RNasin Plus RNase Inhibitor) for 2h. Immune-complex
was washed sequentially with low-salt buffer (20mM Tris–
HCl, pH 8.1, 150mM NaCl, 0.1% SDS, 1% Triton X-100
and 2mM EDTA), with high-salt buffer (20mM Tris–
HCl, pH 8.1, 500mM NaCl, 0.1% SDS, 1% Triton
X-100 and 2mM EDTA), with LiCl buffer (10mM
Tris–HCl, pH 8.1, 250mM LiCl, 1% NP-40, 1%
deoxycholate and 1mM EDTA), and with TE buffer
(10mM Tris pH 8.0, 1mM EDTA). Immune-complex
was eluted with elution buffer (1% SDS, 0.1M NaHCO3
and 50U/ml RNasin Plus RNase Inhibitor). The
crosslinking was reversed by incubation with 200mM
NaCl at 65 C for at least 2h. After digestion with
0.4mg/ml Proteinase K (Invitrogen) at 42 C for 45min
and 1mg/ml of RQ1 Rnase-free Dnase (Promega) at
37 C for 15min, respectively, RNA was extracted by
RNeasy Mini Kit (Qiagen) and subjected to ﬁrst-strand
cDNA synthesis with random primer or Oligo-(dT)15–18
by using the Omniscript Reverse Transcription Kit
(Qiagen). cDNA was ampliﬁed by PrimeSTARTM HS
DNA Polymerase (Takara Bio Inc.) with two sets of
primers against tau introns 9 and 10: one set primers:
Forward 50-AGGCGGGTCCAGGGTGGCGTGTCAC
TCATCC-30, Reverse 50-CTAATAATTCAAGCCACAG
CACGGCGCATGGGACG-30; another set of primers:
Forward 50-AGGGTGGCGCATGTCACTCATCGAAA
GTGGAGGCG-30, Reverse 50-GGATTTATTCTATG C
AGTGTCTCGCAAGTGTACGC-30. An initial denatur-
ation for 5min at 98 C was followed by 30 cycles with
denaturation for 10s at 98 C, annealing for 15s at 55 C,
polymerization for 30s at 72 C and a ﬁnal extension for
10min at 72 C. PCR products were separated on a 1.5%
agarose gel and visualized by ethidium bromide staining.
RESULTS
SC35 promotes tau exon 10 inclusion
To elucidate the role of SC35 on tau exon 10 splicing, we
co-transfected mini-tau gene pCI/SI9–SI10, consisting of
tau exons 9, 10 and 11, part of introns 9 (SI9) and 10
(SI10) (31) together with various amount of pCEP4/
SC35 into HEK-293T cells. The transfected cells were har-
vested at 48h and analyzed for the splicing product of tau
exon 10 by reverse transcription (RT)–PCR. We found
that overexpression of SC35 promotes the tau exon 10
inclusion concentration dependently. The ratio of inclu-
sion/exclusion of tau exon 10 increased along with trans-
fection concentration and the peak appeared at 0.8mg/well
pCEP4/SC35 transfection (Figure 1A). To examine
whether the effect of SC35 on tau exon 10 splicing was
cell type speciﬁc, we also co-transfected pCI/SI9–SI10 and
Figure 1. SC35 promotes tau exon 10 inclusion. (A) SC35 promoted
tau exon 10 inclusion dose dependently. The pCI/SI9–SI10 mini-tau-
gene was co-transfected with different amount of pCEP4-SC35 into
HEK-239T cells. Total RNA was subjected to RT–PCR for measure-
ment of tau exon 10 splicing after 36h transfection. (B) SC35 promoted
tau exon 10 inclusion cell-type independently. pCI/SI9–SI10 was
co-transfected with pCEP4/SC35 into various cell lines indicated
under each panel. Tau exon 10 splicing was measured by RT–PCR
after 36h transfection. (C and D) siRNA of SC35 suppressed tau
exon 10 inclusion. pCI/SI9–SI10 was co-trasnfected with siRNA of
SC35 into N2a cells for 48h, and then the splicing products of tau
exon 10 of mini gene (C) and endogenous mouse tau (D) were
measured by RT–PCR. The same amount of scramble siRNA was
used for controls. The data are presented as mean±SD. **P<0.01.
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found that SC35 promoted tau exon 10 inclusion in these
four types of cells as well (Figure 1B). Thus, SC35
promotes tau exon 10 inclusion.
To conﬁrm the effect of SC35 on the promotion of tau
exon 10 inclusion, we transfected siRNA of SC35 or con-
trol siRNA with pCI/SI9–SI10 into N2a cells to knock
down SC35 expression and then measured the splicing
products by RT–PCR. We found that as compared with
control siRNA, siRNA of SC35 suppressed exon 10 inclu-
sion and decreased the ratio of tau exon 10 inclusion to
exclusion signiﬁcantly (Figure 1C).
To determine the role of SC35 in alternative splicing of
endogenous tau exon 10, we knocked down the expression
of SC35 by siRNA of SC35 in N2a cells and then
measured the splicing products of mouse tau exon 10 by
RT–PCR. We observed that siRNA of SC35 suppressed
mouse 4R-tau expression and decreased the ratio of
3R-tau/4R-tau signiﬁcantly (Figure 1D), which suggests
that SC35 also works on endogenous tau and promotes
tau exon 10 inclusion.
SC35 binds to the pre-mRNA of tau via SC35-like
element of exon 10
To determine the molecular mechanism by which SC35
promotes the inclusion of tau exon 10, we co-transfected
pCI/SI9–SI10 with pCEP4/SC35-HA into HEK-293T
cells, and immunoprecipitated SC35 with anti-HA
antibody from the cell lysates. The co-immunoprecipitated
pre-mRNA of tau with SC35 by anti-HA was ampliﬁed
with RT–PCR by using two kinds of primers, random
primer and oligo dT primer, for reverse transcription
and two sets of primers against introns 9 and 10 of tau
to get 194 and 294bp of PCR products, respectively
(Figure 2A). We observed that pre-mRNA of the
mini-tau-gene was co-immunoprecipitated with SC35
(Figure 2A and B), suggesting that SC35 could act on
the pre-mRNA of tau.
Next, we determined which domain of SC35 was re-
sponsible for recruitment to exon 10 of pre-mRNA of
the mini-tau-gene. SC35 contains one RNA-recognition
motif (RRM) at its N-terminal half and a characteristic
SR-rich protein–protein interaction domain at its
C-terminus. We transfected a set of previously character-
ized domains of SC35 (Figure 2C) together with the
pCI-SI9/SI10 mini-tau-gene into HEK-293T cells. After
48h transfection, RNA-IP was also used to detect
the binding ability between the fragments of SC35 and
pre-mRNA of the mini-tau-gene. We found that HA-
SC351–117 showed the strongest binding ability to the
mini-tau-gene among the SC35 fragments (Figure 2D).
However, only SC35FL and SC351–191 promoted tau
exon 10 inclusion (Figure 2E). These results indicate that
SC35 binds with pre-mRNA of mini-tau-gene through its
RRM and that both RRM and RS domains are required
to promote tau exon 10 inclusion.
SC35-dependent splicing enhancers are known to con-
tain UGCNGYY sequence (37). A SC35-like enhancer
located at the 50-end of tau exon 10 contains the
sequence TGCAGAT (38). Whether the binding between
SC35 and pre-mRNA of tau exon 10 depends on SC35-
like enhancer remains elusive. To answer this question,
HA-tagged SC35 was overexpressed in HEK-293T cells
and puriﬁed using Protein G beads crosslinked with
anti-HA monoclonal antibody. Two major forms of
SC35 were eluted in the ﬁrst fraction, and only one form
was found in fractions 2 and 3 (Figure 3A, left panel). It is
well-known that phosphorylation affects the gel mobility
Figure 2. SC35 acts on exon 10 of tau pre-mRNA to promote tau exon
10 inclusion. (A) Tau pre-mRNA could be immunoprecipitated by
SC35. pCI/SI9–SI10 was co-transfected with pCEP4/SC35-HA into
HEK-293T cells. SC35 was immunoprecipitated with anti-HA
antibody. Co-immunoprecipitated pre-mRNA of tau with SC35 was
determined by RT–PCR with random primer or oligo-dT for
generating cDNA and with two sets of primers speciﬁc to introns
9 and 10 as indicated for amplifying the cDNA derived from tau
pre-mRNA. The RT–PCR product was separated by agarose electro-
phoresis and quantitated by densitometry and presented in B from
two separated experiments. (C) Schematic of SC35 deletion mutants.
(D) Tau pre-mRNA was immunoprecipitated by deletion mutants of
SC35 differentially. Different deletion mutants of SC35 showed in panel
C tagged with HA were overexpressed in pCI/SI9–SI10 transfected
HEK-293T cells. RNA-IP was carried out with anti-HA antibody
and co-immunoprecipitated pre-mRNA of tau was measured by RT–
PCR as in panel A. Total pre-mRNA of tau, Input, was also measured
by RT–PCR with same primers. The immunoprecipitated deletion mu-
tations of SC35 were examined by western blot using anti-HA antibody
(lower panel). (E) Deletion mutations of SC35 promoted tau exon 10
inclusion differentially. pCI/SI9–SI10 was co-transfected with different
deletion mutants of SC35 into HEK-293T. Total RNA was extracted
and subjected to RT–PCR for measurement of tau exon 10 splicing
after 36h transfection.
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down the mobility of SC35, we immunopuriﬁed SC35
with anti-HA crosslinked protein G beads, and then
dephosphorylated it with alkaline phosphatase. The
dephosphorylated product was subjected to western blots
with anti-HA and 1H4, an antibody against phospho-SR
proteins. We found that upon dephosphorylation with
alkaline phosphatase, the upper band of SC35 dis-
appeared and the lower SC35 band was not recognized
by antibody 1H4 (Figure 3A, right two panels). These
results indicated that the upper SC35 band was the pho-
sphorylated SC35 and the lower band was the unphos-
phorylated one. To determine whether SC35 binds to
tau RNA and whether its phosphorylation affects the
binding, EMSA was carried out. We observed that
the phosphorylated SC35 bound RNA oligomer contain-
ing SC35-like sequence in a dose-dependent manner
(Figure 3B, lanes 2–4), whereas the unphosphorylated
SC35 completely lost the binding ability. The binding
activity of SC35 to the RNA oligomer was decreased
when CAGATA was deleted in the SC35-like ESE.
These data suggest that SC35 binds SC35-like enhancer
speciﬁcally and the binding requires its phosphorylation.
To validate our hypothesis that SC35 promotes tau
exon 10 inclusion by acting on the SC35-like enhancer
of exon 10 of tau pre-mRNA, we transfected the wild-
type and the mutant SI9/SI10 tau mini-genes alone or
together with pCEP4/SC35 into HEK-293T cells. The
level of the alternative splicing of exon 10 was detected
by RT–PCR. The results showed that mutation of A to G
at the fourth base pair of exon 10 increased the inclusion
of exon 10 (Figure 3D, lane 3), while mutation of G to A
at the ﬁfth base pair of exon 10 dramatically inhibited
the exon 10 inclusion (Figure 3D, lane 5). Deletion of
Figure 3. SC35 promotes tau exon 10 inclusion through SC35-like enhancer. (A) SC35 was immunopuriﬁed by anti-HA. SC35 tagged with HA was
overexpressed in HEK-293T cells and immunopuriﬁed with anti-HA-crosslinked protein G beads. Different elution fractions (left panel) were
subjected to western blot analysis with anti-HA. Immunoprecipitated SC35 without elution was dephosphorylated with alkaline phosphatase and
determined by anti-HA and 1H4, an antibody to phosphorylated SR proteins. E1, elution fraction 1; E2, elution fraction 2; E3, elution fraction 3;
ALP, alkaline phosphatase. (B) SC35 bound to RNA of tau exon 10. Immunopuriﬁed SC35 (E1 and E2) was incubated with tau pre-mRNA
(tau-RNA) or SC35-like enhancer deleted tau pre-mRNA (tau-RNASC35 like) pre-labeled with g-
32P ATP. The incubation products were subjected to
native-gel electrophoresis. After drying, the gel was analyzed with phosphoimaging device (BAS-1500, Fujiﬁlm). (C) Schematic of mutations of
mini-tau-gene on SC35-like enhancer of tau exon 10. (D) Mutations of SC35-like enhancer affected SC35 promoted tau exon 10 inclusion. Different
mutants of mini-tau-gene, pCI/SI9–SI10, at SC35 like enhancer were transfected alone or together with pCEP4/SC35. RT–PCR was carried out to
measure tau exon 10 splicing after 36h transfection.
6166 Nucleic Acids Research, 2011,Vol.39, No. 14SC35-like enhancer, GCAGATA, also suppressed the exon
10 inclusion (Figure 3D, lane 7). Overexpression of SC35
increased tau exon 10 inclusion markedly in SI9–SI10
and in SI9–SI10E10A4G, but much less in SI9–SI10E10G5A
and SI9–SI10E102–8 (Figure 3D). These results verify that
SC35-like enhancer acts as a splicing enhancer and that
the promotion of tau exon 10 inclusion by SC35 depends
on the SC35-like enhancer located on tau exon 10.
SC35 interacts with Dyrk1A
To address whether Dyrk1A regulates SC35 activity in
splicing, we ﬁrst studied the interaction between SC35
and Dyrk1A. GST-pull down was used to detect the
protein–protein interaction in vitro. We found that
Dyrk1A from rat brain extract was pulled down with
GST-SC35, but not with GST itself (Figure 4A). To
further validate the interaction, co-immunoprecipitation
and confocal microscopy were employed in cultured
cells. Dyrk1A could be co-immunoprecipitated with
HA-SC35 by anti-HA antibody (Figure 4B), conﬁrming
the interaction between SC35 and Dyrk1A.
To study the interaction of SC35 with Dyrk1A in intact
cells, we coexpressed HA-SC35 and Dyrk1A in HeLa cells
and then immunostained the cells with anti-HA and anti-
Dyrk1A. By employing confocal microscopy, we observed
that both Dyrk1A and SC35 were mainly located in the
nucleus, colocalized and enriched in the nuclear speckles,
giving further evidence to their possible interaction in
cultured cells (Figure 4C).
To map the domain of SC35 that interacts with
Dyrk1A, HA-tagged full-length and various deletion
mutations of SC35, HA-SC351–191, HA-SC351–117, HA-
SC3588–221 and HA-SC35108–221, were coexpressed with
Dyrk1A, respectively, in HEK-293T cells for co-immuno-
precipitation assays or in HeLa cells for confocal micros-
copy. The results from co-IP showed that Dyrk1A was
co-immunoprecipitated by SC35, SC351–191 or SC351–117,
but not by SC3588–221 or SC35108–221 (Figure 5A), suggest-
ing that the interaction between SC35 and Dyrk1A was
through the N-terminal domain of SC35. HA-SC35FL,
HA-SC351–191 and HA-SC351–117 also showed subcellular
colocalization with Dyrk1A, and they were enriched in the
nuclear speckles (Figure 5B). However, HA-SC3588–221
and HA-SC35108–221 showed some what different distribu-
tion patterns from that of Dyrk1A, although they were
both in the nucleus. These results further support that
the N-terminus of SC35 interacts with Dyrk1A.
Dyrk1A inhibits SC350s activity to promote tau
exon 10 inclusion
Our observations of the physical interaction between SC35
and Dyrk1A led us to further investigate the functional
relationship between them. We incubated GST-SC35 with
Dyrk1A in vitro and found that GST-SC35, but not GST,
was phosphorylated by Dyrk1A in an enzyme
concentration-dependent manner (Figure 6A and B).
Then we studied the impact of Dyrk1A on the bio-
logical activity of SC35. pCI/SI9–SI10 was co-transfected
with pcDNA3/Dyrk1A or pcDNA3/Dyrk1AK188R alone,
or in combination with pCEP4/SC35, and the amounts of
exon 10 inclusion and exclusion were measured by RT–
PCR. We found that Dyrk1A, but not Dyrk1AK188R,a
dead enzyme, suppressed SC350s activity to promote tau
exon 10 inclusion (Figure 6C). These results suggest that
phosphorylation of SC35 by Dyrk1A inhibits its activity
to promote tau exon 10 inclusion.
To conﬁrm that Dyrk1A suppresses tau exon 10 inclu-
sion, we knocked down the expression of Dyrk1A by its
siRNA (26) in pCI/SI9–SI10 transfected HEK-293FT cells
and then measured splicing products by RT–PCR. We
observed that transfection of Dyrk1A siRNA enhanced
the SC35 promoted tau exon 10 inclusion dose depend-
ently (Figure 6D). To determine the role of Dyrk1A in
endogenous tau exon 10 splicing, we transfected siRNA
of Dyrk1A into N2a or SH-SY5Y cells, both expressing
tau, for 48h, and then measured the products of the
splicing by RT–PCR. We found that transfection with
Figure 4. SC35 interacts with Dyrk1A. (A) Dyrk1A was pulled down
from rat brain extract by GST-SC35. GST-SC35 or GST coupled
onto glutathione Sepharose was incubated with rat brain extract.
After washing, bound proteins were subjected to western blots using
anti-GST and anti-Dyrk1A antibody. (B) Dyrk1A could be
co-immunoprecipitated by HA-SC35 using anti-HA antibody. SC35
tagged with HA and Dyrk1A were coexpressed in HEK-293T cells
for 48h. The cell extract was incubated with anti-HA antibody
coupled onto protein G beads. The bound proteins were subjected
to western blots using antibodies indicated under each blot.
(C) Colocalization of SC35 with Dyrk1A in nucleus. HA-SC35 and
Dyrk1A were co-transfected into HeLa cells. After a 48h transfection,
the cells were ﬁxed and immunostained by anti-HA or anti-Dyrk1A
and followed by TRITC-anti-rabbit IgG or FITC-anti-mouse IgG.
Hoechst was used for nuclear staining.
Nucleic Acids Research, 2011,Vol.39, No. 14 6167Dyrk1A siRNA signiﬁcantly increased 4R-tau expression
in the both cells (Figure 6E), suggesting that Dyrk1A also
suppresses exon 10 inclusion of endogenous tau.
DISCUSSION
The present study provides the ﬁrst directly experimental
evidence that SC35 acts on the SC35-like enhancer located
at the 50-end of tau exon 10 and promotes tau exon 10
inclusion. Dyrk1A interacts with and phosphorylates
SC35 and inhibits its activity to promote tau exon 10 in-
clusion. Taken together with our recent ﬁndings
that Dyrk1A phosphorylates splicing factor SF2/ASF
and suppresses SF2/ASF-promoted tau exon 10 inclusion
(26,39), we conclude that up-regulation of Dyrk1A in DS
individuals due to trisomy 21 may suppress the function
of SC35 and SF2/ASF in promoting tau exon 10 inclusion
and lead to increase in 3R-tau expression, which may
initiate or accelerate tau pathology in DS brain. In
addition, overproduction of amyloid-b peptide, as a
result of an extra copy of the gene for amyloid-b precursor
protein located on chromosome 21, in DS brain may also
initiate or accelerate tau pathology. Therefore, the early
onset of tau pathology in DS could result from the
overexpression of both Dyrk1A and amyloid-b precursor
protein.
Tau exon 10 is ﬂanked by large introns 9 (13.6kb) and
10 (3.8kb). It has two weak splice sites, a weak 50 splice
site and a weak 30 splice site (10,12,38). Several cis-
elements in exon 10 and intron 10, which modulate the
use of the weak 50- and 30 splice sites, have been identiﬁed
and extensively characterized (20,21). The 50 end of exon
10 contains three ESEs (exonic splicing enhancer), a
SC35-like enhancer, a polypurine enhancer (PPE) and an
A/C-rich enhancer (ACE). Splicing factors act on these
elements and regulate the alternative splicing of tau exon
10. Mutations in these elements, including 280, N279K
and L284L, cause FTDP17.
SC35-dependent splicing enhancers have the sequence
of UGCNGYY (where Y=C or U, and N is any base)
(37). The 50-end of exon 10 of tau pre-mRNA contains the
sequence, UGCAGAU, that matches with the above con-
sensus sequence and was named as SC35-like enhancer
(38). The present study showed that deletion of this elem-
ent resulted in increased tau exon 10 exclusion, supporting
that the SC35-like element acts as an enhancer. Mutation
of guanosine to adenosine (UGCAGAU to UGCAAAU)
led tau exon 10 exclusion, conﬁrming that the G at base 5
is required for the enhancer. However, mutation of adeno-
sine to guanosine at base 4 (UGCAGAU to UGCGGAU)
increased tau exon 10 inclusion, suggesting that the fourth
base at SC35-dependent splicing enhancer, UGCNGYY,
could modulate its splicing activity.
As implied by the name, SC35 acts on SC35-dependent
splicing enhancer and promotes the exon inclusion. In the
present study, by employing EMSA and RNA-IP, we
Figure 5. N-terminus of SC35 interacts with Dyrk1A. (A) Dyrk1A was co-immunoprecipitated by N-terminus of SC35 using anti-HA antibody.
Dyrk1A was coexpressed with different deletion mutations of SC35 tagged with HA in HEK-293T cells for 48h. The cell extract was incubated
with anti-HA coupled to protein G beads. The bound proteins were subjected to western blots using antibodies indicated at the right of each blot.
Dyrk1A in cell lysate was used as loading control (lower panel). (B) colocalization of N-terminus of SC35 with Dyrk1A in nucleus. HA-SC351–191,
HA-SC351–117, HA-SC3588–221 or HA-SC35108–221 was co-transfected with Dyrk1A respectively into HeLa cells. After a 48-h transfection, the cells
were ﬁxed and immunostained by anti-HA or anti-Dyrk1A and followed by TRITC-anti-rabbit IgG or FITC-anti-mouse IgG. Hoechst was used for
the staining of nuclei.
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enhancer to promote the exon 10 inclusion and that the
regulatory efﬁciency is dependent on SC35-like enhancer
sequence. It is well known that in SR proteins, RRM
interacts with the pre-mRNA and RS domain promotes
protein–protein interactions within the splicing complex.
SC35 has a RRM at its N-terminus and a RS domain at
C-terminus. In this study, we observed that RRM bound
to the pre-mRNA most strongly, and RS domain weakly
interacts with the pre-mRNA. However, both RRM and
RS domains are required for promoting tau exon 10
inclusion.
It has been reported that the serine residues within the
RS domains of SR proteins are extensively phosphory-
lated. First, this phosphorylation appears to inﬂuence the
subcellular localization of SR proteins (22,24). Second,
phosphorylation affects protein interactions involving
SR proteins (23,40). Both of them may change the
ability of SR proteins in splicing function. To date,
several kinases, including SR-protein kinases 1 and 2
(SRPK1 and SRPK2), the cell cycle-dependent dual spe-
ciﬁcity kinase (Clk/Sty), Akt/protein kinase B and DNA
topoisomerase I (Topo I), have been reported to phos-
phorylate and regulate localization and function of SR
proteins (22,24,25,41,42). SC35 is also phosphorylated
by GSK-3b at N-terminal of SC35 primed by other
kinases. Inhibition of GSK-3 increases 4R-tau expression
(43). Amyloid-b peptide treatment reduces 4R-tau expres-
sion via the GSK-3b-SC35 pathway (44).
We previously found Dyrk1A phosphorylates SR
proteins SF2/ASF and regulates their function in tau
splicing (26). SF2/ASF plays a very important role in
tau exon 10 inclusion (45). Dyrk1A phosphoryl-
ates and drives SF2/ASF into nuclear speckles, and pre-
vents it from facilitating tau exon 10 inclusion (26).
Overexpression of Dyrk1A due to trisomy 21 in DS
brain leads to increased 3R-tau/4R-tau ratio, an imbal-
ance that is known to associate with neuroﬁbrillary
Figure 6. Dyrk1A phosphorylates SC35 and suppresses SC35 promoted tau exon 10 inclusion. (A) autoradiography of SC35 phosphorylation by
Dyrk1A in vitro. Recombinant GST-SC35 was incubated with various concentrations of Dyrk1A indicated above each lane for 30min at 30 C and
separated by SDS–PAGE and visualized with Coomassie blue staining (lower panel). The last lane is Dyrk1A alone, without GST-SC35. After drying
the gel, the
32P incorporated into SC35 was measured by using a phosphorimaging device (BAS-1500, Fuji) (upper panel). (B) The incorporated
32P
into SC35 was by different concentration of Dyrk1A. (C) Dyrk1A, but not Dyrk1AK188R, inhibited tau exon 10 inclusion promoted by SC35.
pcDNA/Dyrk1A or pcDNA/Dyrk1AK188R was transfected only or together with SC35 into HEK-293T. Total RNA was subjected to RT–PCR for
measurement of tau exon 10 splicing after 36h transfection. (D) siRNA of Dyrk1A enhanced SC35-promoted tau exon 10 inclusion. pCEP4/SC35
was co-transfected with various concentration of siRNA of Dyrk1A into pCI/SI9–SI10 transfected HEK-293FT cells for 48h, and the products of
tau exon 10 splicing were measured by RT–PCR. (E) siRNA of Dyrk1A promoted 4R-tau expression. N2a or SH-SY5Y cells were transfected with
Dyrk1A siRNA for 48h, and then 3R-tau and 4R-tau were measured by RT–PCR. The same amount of scramble siRNA was used for controls.
*P<0.05; **P<0.01.
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(26). Mutations of L266V, G272V, D280, E9+33, E10+19
and E10+29 result in an increase in tau exon 10 exclusion.
The molecular mechanism of 3R-tau associated neuroﬁb-
rillary degeneration in Pick’s disease is unclear. It was
reported that as compared with controls, the mRNA
level of Dyrk1A in the hippocampus of patients with
AD is increased (46). Our unpublished data also demon-
strated that Dyrk1A was truncated and activated by
calpain I in AD brain. Moreover, calpain I also pro-
teolyzes GSK-3b and PKA-Ca, which promotes tau
exon 10 exclusion and 3R-tau expression (47–49).
Dyrk1A is a proline directed Ser/Thr kinase and phos-
phorylates Thr or Ser at the consensus motif of
RX(X)T/SP of numerous proteins. SC35 harbors four
Dyrk1A-consensus motifs. They are located at both
RRM and RS domain. However, the exact phosphoryl-
ation sites of SC35 by Dyrk1A remain to be determined.
In the present study, we demonstrated that Dyrk1A inter-
acted with SC35 through the RRM of SC35,
phosphorylated SC35 effectively and suppressed tau
exon 10 inclusion, suggesting that an upregulation of
Dyrk1A may cause an imbalance in the alternative
splicing of tau exon 10, leading to or accelerating tau path-
ology in DS, AD and related disorders via ASF and SC35,
as well as other splicing factors.
In summary, SC35 speciﬁcally binds to pre-mRNA
product of the SC35-like enhancer on tau exon 10 both
in vitro and in vivo. SC35 promotes tau exon 10 inclusion
that is dependent on the SC35-like enhancer of SC35.
Dyrk1A interacts and phosphorylates SC35, resulting in
an inhibition of tau exon 10 inclusion promoted by SC35.
These ﬁndings provide a new insight into mechanisms of
the regulation of tau exon 10 splicing and shed new light
into the dysregulation of tau exon 10 splicing in DS where
there is an extra copy of Dyrk1A. These ﬁndings can help
in development of novel therapeutic strategies to prevent
or inhibit neuroﬁbrillary degeneration in tauopathies.
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